Share this video  

ESMO 2021 | Highlights for skin cancer at ESMO 2021

Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses some of the highlights of skin cancer research at ESMO 2021. Interesting trials included KEYNOTE-716 (NCT03553836) for adjuvant therapy in high-risk melanoma, RELATIVITY-047 (NCT03470922) for relatlimab and nivolumab in advanced melanoma, and SECOMBIT (NCT02631447) for the integration of BRAF inhibitors with immunotherapy. Another highlight was the research on treatment of brain metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Luke reports DSMB: Abbvie, Immutep. Scientific Advisory Board: (no stock) 7 Hills, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.AI, Pyxis, Tempest.

Dr Luke reports consultancy with compensation: Abbvie, Alnylam, Avillion, Bayer, Bristol-Myers Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor.

Dr Luke reports research support: (all to institution for clinical trials unless noted) AbbVie, Agios (IIT), Astellas, Astrazeneca, Bristol-Myers Squibb (IIT & industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT & industry) Replimmune, Rubius, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor/

Dr Luke reports patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)